Ferrari, Roberto
Camici, Paolo G.
Crea, Filippo
Danchin, Nicolas
Fox, Kim
Maggioni, Aldo P.
Manolis, Athanasios J.
Marzilli, Mario
Rosano, Giuseppe M. C.
Lopez-Sendon, José L.
Article History
First Online: 7 September 2017
Competing interests
: R.F. has received honoraria for steering committee membership and consulting from Novartis and Servier; and for speaking and support for travel to study meetings from Amgen, Bayer, Boehringer Ingelheim, Merck Serono, and Servier. P.G.C. is a consultant for Servier, is part of Board meetings of AstraZeneca, and has received speaking honoraria from Menarini and Servier. F.C. has received honoraria for speaking from BMS, Menarini, Novartis, Sanofi, and Servier; and received grants from Biotronik and Boeringher Ingelheim. K.F. has received personal fees, honoraria, and/or travel expenses from Armgo, AstraZeneca, Broadview Ventures, CellAegis, Servier, and TaurX; and is a director of Vesalius Trials Ltd. A.P.M. has received honoraria for steering committee membership from Bayer, Cardiorentis, and Novartis; received support for travel to study meetings from the same companies; and received personal fees for speaking activities from Amgen, Lilly, Sanofi, and Servier. J.L.L.-S. has received honoraria for steering committee membership from AstraZeneca, Bayer, Boehringer-Ingelheim, GlaxoSmithKline, Menarini, Merck, Novartis, Pfizer, Sanofi, and Servier; received honoraria for speaking from Amgen and Sanofi; and received honoraria for consultancy from Boehringer Ingelheim and Menarini. The other authors declare no competing interests.